BR0016084A - Método para melhorar biodisponibilidade de derivados de esporão do centeio e composição farmacêutica de liberação prolongada - Google Patents

Método para melhorar biodisponibilidade de derivados de esporão do centeio e composição farmacêutica de liberação prolongada

Info

Publication number
BR0016084A
BR0016084A BR0016084-9A BR0016084A BR0016084A BR 0016084 A BR0016084 A BR 0016084A BR 0016084 A BR0016084 A BR 0016084A BR 0016084 A BR0016084 A BR 0016084A
Authority
BR
Brazil
Prior art keywords
bioavailability
derivatives
sustained
rye
spur
Prior art date
Application number
BR0016084-9A
Other languages
English (en)
Inventor
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of BR0016084A publication Critical patent/BR0016084A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODO PARA MELHORAR BIODISPONIBILIDADE DE DERIVADOS DE ESPORãO DO CENTEIO E COMPOSIçãO FARMACêUTICA DE LIBERAçãO PROLONGADA". Um método de melhorar a biodisponibilidade de derivados de esporão do centeio administrados usando-se sistemas de distribuição por liberação prolongada inclui combinar um derivado de esporão do centeio ou mistura deste com um agente de tumefação hidrofílico farmaceuticamente aceitável ou mistura deste e um ou mais excipientes farmaceuticamente aceitáveis. A biodisponibilidade das formulações de liberação prolongada da presente invenção é pelo menos igual à biodisponibilidade do derivado de esporão do centeio ou mistura deste administrado usando-se um sistema de distribuição convencional. As composições de liberação prolongada que melhoram a biodisponibilidade também são fornecidas. Os métodos e as composições de acordo com a presente invenção podem fornecer características de liberação prolongada enquanto melhoram a biodisponibilidade dos derivados de esporão do centeio.
BR0016084-9A 1999-12-03 2000-11-30 Método para melhorar biodisponibilidade de derivados de esporão do centeio e composição farmacêutica de liberação prolongada BR0016084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45436499A 1999-12-03 1999-12-03
PCT/EP2000/012302 WO2001039742A2 (en) 1999-12-03 2000-11-30 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof

Publications (1)

Publication Number Publication Date
BR0016084A true BR0016084A (pt) 2002-08-06

Family

ID=23804314

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016084-9A BR0016084A (pt) 1999-12-03 2000-11-30 Método para melhorar biodisponibilidade de derivados de esporão do centeio e composição farmacêutica de liberação prolongada

Country Status (17)

Country Link
US (1) US20020114836A1 (pt)
EP (2) EP1512403A1 (pt)
JP (1) JP4965784B2 (pt)
KR (1) KR100504618B1 (pt)
CN (1) CN100400042C (pt)
AT (1) ATE288269T1 (pt)
AU (1) AU2165301A (pt)
BR (1) BR0016084A (pt)
CA (1) CA2393344C (pt)
DE (1) DE60017938T2 (pt)
ES (1) ES2236017T3 (pt)
HK (1) HK1048254B (pt)
MX (1) MXPA02005291A (pt)
PL (1) PL202357B1 (pt)
PT (1) PT1235574E (pt)
RU (1) RU2256454C2 (pt)
WO (1) WO2001039742A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520390A (ja) * 2003-03-14 2006-09-07 ムルイェ、ニルマル 徐放性錠剤の製造方法
TW200517106A (en) * 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
EP1904067B2 (en) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
CN101590058B (zh) * 2009-07-02 2011-04-27 苏州东瑞制药有限公司 含有甲磺酸二氢麦角隐亭a的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
BE880713A (fr) * 1978-12-21 1980-06-19 Sandoz Sa Nouvelles compositions pharmaceutiques solides a base d'alcaloides de l'ergot de seigle, permettant une liberation controlee de ce principe actif
JPS615010A (ja) * 1984-06-18 1986-01-10 Tooa Eiyoo Kk 水素添加麦角アルカロイド徐放性製剤及びその製法
HU195729B (en) * 1985-02-05 1988-07-28 Sandoz Ag Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
SI8710406B (sl) * 1987-03-11 1998-08-31 Lek Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications

Also Published As

Publication number Publication date
EP1235574B1 (en) 2005-02-02
CA2393344C (en) 2009-09-01
KR20020063197A (ko) 2002-08-01
HK1048254B (zh) 2005-06-03
DE60017938T2 (de) 2006-01-12
EP1235574A2 (en) 2002-09-04
US20020114836A1 (en) 2002-08-22
ES2236017T3 (es) 2005-07-16
WO2001039742A3 (en) 2001-12-13
JP2003515549A (ja) 2003-05-07
DE60017938D1 (de) 2005-03-10
PL356387A1 (en) 2004-06-28
JP4965784B2 (ja) 2012-07-04
AU2165301A (en) 2001-06-12
RU2256454C2 (ru) 2005-07-20
PT1235574E (pt) 2005-05-31
RU2002117655A (ru) 2004-01-27
HK1048254A1 (en) 2003-03-28
PL202357B1 (pl) 2009-06-30
ATE288269T1 (de) 2005-02-15
CA2393344A1 (en) 2001-06-07
EP1512403A1 (en) 2005-03-09
CN1433311A (zh) 2003-07-30
KR100504618B1 (ko) 2005-08-04
MXPA02005291A (es) 2004-06-21
WO2001039742A2 (en) 2001-06-07
CN100400042C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
ES2235234T3 (es) Comprimido de rapida disolucion de bromhidrato de galantamina.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
AU2002316811A1 (en) Stable formulation of modified glp-1
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
EP0966966A3 (en) Nefazodone dosage form
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
CA2326198A1 (en) Cosolvent formulations
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
BR0016084A (pt) Método para melhorar biodisponibilidade de derivados de esporão do centeio e composição farmacêutica de liberação prolongada
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
WO2000054763A3 (en) Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone
BR0014308A (pt) Formulação de veìculo farmacêutica
ITMI912044A1 (it) Composizione farmaceutica solida per uso orale a base di dapiprazolo
RS20060413A (en) Non-disintegrating oral solid composition of high dose of water soluble drugs
DK0483320T3 (da) Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf
PT730474E (pt) Formulacoes de estramustina possuindo propriedades farmacologicas melhoradas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.